Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer.
Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer.
复制标题
DOI：
10.1097/md.0000000000012806
复制
发表时间：
2018-10
期刊：
影响因子：
1.6
通讯作者：
Xie L
中科院分区：
文献类型：
--
作者：
Mao Z;Ji A;Yang K;He W;Hu Y;Zhang Q;Zhang D;Xie L
前列腺癌基因3（PCA 3）、人激肽释放酶2和miRNA-141是有希望的前列腺癌（Pca）特异性生物标志物。我们的目的是评估前列腺活检患者外周血中PCA 3、人腺激肽释放酶2（hk 2）和miRNA-141 mRNA的检测。并探讨联合检测前列腺特异性抗原（PSA）在PCa早期诊断中的价值。根据病理诊断结果将100例患者分为2组。采用实时定量PCR（qRT-PCR）检测外周血中PCA 3、hk 2和miRNA-141的mRNA水平。同时，分析患者使用的临床结局。我们比较了这些不同的结果，以评估新的分子标记物的价值。Pca组中PCA 3、hK 2和miR-141的mRNA水平均显著高于BPH组。PSA预测Pca诊断的敏感性最高（76.7%），PCA 3的特异性最高（82.5%）。PCA_3、PSA、hK_2联合应用可明显改善受试者的曲线下面积（AUC）-受试者工作特征（ROC）曲线，尤其是PSA为4- 10 ng/mL的受试者。PCA 3、hK 2和miRNA-141是Pca的生物标志物，特别是在PSA灰区患者中具有潜在的临床应用价值。结合PCA 3、PSA和hK 2在预测Pca方面优于单独的生物标志物。
The prostate cancer gene 3 (PCA3), human kallikrein 2, and miRNA-141 are promising prostate cancer (Pca) specific biomarkers. Our aim was to evaluate the detection of PCA3, human glandular kallikrein 2 (hk2), and miRNA-141 mRNA in peripheral blood of patients received prostate biopsy. What's more, we want to detect the value of combination of PSA (prostate specific antigen) in the early diagnosis of PCa. Hundred patients were divided into 2 groups according to the results of pathologic diagnosis. Quantitative real-time PCR (qRT-PCR) was used to evaluate the mRNA of PCA3, hk2, and miRNA-141 in peripheral blood. At the same time, analyze those clinical outcomes used in the patients. We compared these different outcomes to evaluate the value of new molecular markers. The level of mRNA of PCA3, hK2, and miR-141 in Pca group were significantly higher than that in BPH. PSA had the highest sensitivity in predicting Pca diagnosis (76.7%); PCA3 had the highest specificity (82.5%). And the combination of PCA3, PSA, and hK2 improved area under the curve (AUC)-receiver operating characteristic (ROC) curve largely, especially those with PSA 4-10ng/mL. PCA3, hK2, and miRNA-141 were biomarkers of Pca with potential clinical application value, especially in patients with PSA gray area. Combining PCA3, PSA, and hK2 performed better than individual biomarkers alone in predicting Pca.